Drugs / Ceralasertib
Trials 46
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 115 trials | ||||||
| Phase 1 | NCT06754761 | Sep → Oct 2025 | neoplasm | AstraZeneca | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT06929260 | May → Oct 2025 | neoplasm | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT05514132 | Sep 2022 → Oct 2023 overdue | cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05469919 | Jun 2022 → Aug 2023 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04704661 | Aug 2021 → Mar 2027 expected | HER2 positive breast carcinoma, colon carcinoma, endometrial carcinoma, female breast carcinoma +6 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04550104 | Mar 2021 → Mar 2026 overdue | non-small cell lung carcinoma | University of Leeds | Recruiting | No outcome recorded |
| Phase 1 | NCT03669601 | Oct 2019 → Sep 2023 | cancer | CCTU- Cancer Theme | Unknown | No outcome recorded |
| Phase 1 | NCT03770429 | Aug 2019 → Apr 2025 overdue | leukemia, myelodysplastic syndrome | Massachusetts General Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03527147 | Jun 2018 → Mar 2021 | diffuse large B-cell lymphoma | Acerta Pharma BV | Completed | No outcome recorded |
| Phase 1 | NCT03328273 | Jan 2018 → Sep 2021 overdue | B-cell chronic lymphocytic leukemia | Acerta Pharma BV | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03022409 | Sep 2017 → Jan 2021 | head and neck squamous cell carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02630199 | Dec 2015 → Dec 2020 | refractory malignant neoplasm | Samsung Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT02264678 | Oct 2014 → Mar 2025 overdue | — | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02223923 | Jul 2014 → Dec 2025 | refractory malignant neoplasm | Royal Marsden NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 1 | NCT01955668 | Nov → Dec 2013 | B-cell chronic lymphocytic leukemia, prolymphocytic leukemia | AstraZeneca | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02813135 | Aug 2016 → Feb 2031 expected | childhood malignant neoplasm | Gustave Roussy, Cancer Campus, Grand Paris | Recruiting | No outcome recorded |
| Phase 228 trials | ||||||
| Phase 2 | NCT06769126 | Nov 2025 → Dec 2028 expected | small cell lung carcinoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 2 | NCT06680050 | Aug 2025 → Jun 2028 expected | non-small cell lung carcinoma | Mario Negri Institute for Pharmacological Research | Recruiting | No outcome recorded |
| Phase 2 | NCT05941897 | Jun 2023 → Jul 2024 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05582538 | Dec 2022 → Dec 2027 expected | triple-negative breast carcinoma | IFOM ETS - The AIRC Institute of Molecular Oncology | Recruiting | No outcome recorded |
| Phase 2 | NCT05061134 | Aug 2022 → Apr 2024 overdue | melanoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04564027 | Dec 2020 → Feb 2025 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT04417062 | Nov 2020 → Jun 2025 overdue | osteosarcoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04239014 | Aug 2020 → Jan 2021 | ovarian cancer | AstraZeneca | Withdrawn | No outcome recorded |
| Phase 2 | NCT04090567 | Jul 2020 → Dec 2027 expected | BRCA1-related cancer predisposition, BRCA2-related cancer predisposition, Her2-receptor negative breast cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04298008 | Jun 2020 → Dec 2024 | bile duct cancer, chemotherapy-induced toxicity | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04298021 | Jun 2020 → Dec 2024 | bile duct cancer | Seoul National University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04361825 | Jun 2020 → Oct 2023 | small cell lung carcinoma | Se-Hoon Lee | Completed | No outcome recorded |
| Phase 2 | NCT03878095 | Jan 2020 → Mar 2025 overdue | cholangiocarcinoma, high grade malignant neoplasm | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04065269 | Nov 2019 → Aug 2026 overdue | female reproductive organ cancer | Institute of Cancer Research, United Kingdom | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03787680 | Oct 2019 → Jan 2023 overdue | prostate cancer | University of Michigan Rogel Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03740893 | Oct 2019 → Dec 2026 expected | triple-negative breast carcinoma | Institute of Cancer Research, United Kingdom | Recruiting | No outcome recorded |
| Phase 2 | NCT03833440 | Oct 2019 → Oct 2024 | non-small cell lung carcinoma | Assistance Publique Hopitaux De Marseille | Unknown | No outcome recorded |
| Phase 2 | NCT03780608 | Jul 2019 → Dec 2022 | gastric adenocarcinoma, melanoma | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT03682289 | Jan 2019 → Mar 2028 expected | castration-resistant prostate carcinoma, clear cell renal carcinoma, endometrial cancer, malignant pancreatic neoplasm +3 | Rahul Aggarwal | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03801369 | Dec 2018 → Oct 2024 | female breast carcinoma, triple-negative breast carcinoma | Gordon Mills, MD, PhD | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT03579316 | Dec 2018 → Dec 2026 expected | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03428607 | Oct 2018 → Jan 2021 | small cell lung carcinoma | Samsung Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03462342 | Mar 2018 → Jul 2025 | serous adenocarcinoma | University of Pennsylvania | Completed | No outcome recorded |
| Phase 2 | NCT03334617 | Dec 2017 → Sep 2024 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03182634 | Dec 2016 → Nov 2022 | female breast carcinoma | Institute of Cancer Research, United Kingdom | Unknown | Mixed |
| Phase 2 | NCT02937818 | Nov 2016 → Jun 2020 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT02576444 | Nov 2015 → Nov 2019 | cancer | Joseph Paul Eder | Terminated | No outcome recorded |
| Phase 2 | NCT02664935 | May 2015 → Nov 2023 | adenocarcinoma, non-small cell lung carcinoma, squamous cell carcinoma | University of Birmingham | Completed | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT06732401 | Aug 2025 → Jun 2028 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05450692 | Sep 2022 → Oct 2025 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | Missed primary |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT04699838 Background | Apr 2021 → Jan 2027 expected | small cell lung carcinoma | Muhammad Furqan | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03330847 Comparator | Mar 2018 → Nov 2020 overdue | triple-negative breast carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-12-22 | AstraZeneca | Results Update on LATIFY Phase III trial of ceralasertib plus Imfinzi in previously treated advanced non-small cell lung cancer astrazeneca.com ↗
The LATIFY Phase III trial of ceralasertib in combination with Imfinzi (durvalumab) did not meet the primary endpoint of overall survival (OS) versus standard-of-care docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). |
| 2021-05-19 | AstraZeneca | Results AstraZeneca ASCO 2021 data support ambition to revolutionise cancer outcomes by treating earlier and transforming the patient experience astrazeneca.com ↗
showing that this combination demonstrated promising anti-tumour activity in melanoma patients for whom prior anti-PD1 treatment had failed. |
| 2018-04-04 | AstraZeneca | Results AstraZeneca’s early and late-stage oncology portfolio showcased at AACR annual meeting and ELCC astrazeneca.com ↗
The PARP inhibitor olaparib is synergistic with the ATR inhibitor AZD6738 in ATM deficient cancer cells |
| 2017-03-28 | AstraZeneca | Results Astrazeneca to share its robust early science in oncology with the medical community at AACR 2017 astrazeneca.com ↗
Preclinical data uncovering a novel role for the bromodomain protein, BRD4, in regulating DNA replication-stress response, and the potential of the combination of the BRD4 inhibitor, AZD5153, and the ATR inhibitor, AZD6738, in the sustained delay of tumour growth (Abstract #1026) |
All press releases naming this drug 4 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 52 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ceralasertib | “Phase 1 study of ATRinhibition alone or with radiation therapy (PATRIOT) was a first-in-human phase I study of the oral ATR (ataxia telangiectasia and Rad3-related) inhibitor...” PMID 37934611 ↗ Jan 202431“Ceralasertib (AZD6738) is an oral kinase inhibitor of ataxia telangiectasia and Rad3 related protein, which is a master regulator of DDR.” PMID 35790315 ↗ Jul 2022 “Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase ATR” NCT06754761 ↗ |
| Known as | Atr kinase inhibitor azd6738 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4285417 ↗ |
| Known as | AZD6738 | “Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase, ATR, with good selectivity against other phosphatidylinositol...” NCT05514132 ↗24“Durvalumab 1500mg via IV administered for every 4weeks(fixed dosing for subjects \> 30 kg body weight) in Day 1 of each cycle and AZD 6738 240mg bid per os administered in each...” NCT04361825 ↗ “Ceralasertib (AZD6738) is a potent, selective inhibitor of the serine/threonine-specific protein kinase ATR” NCT06754761 ↗ “Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects” NCT04361825 ↗ “Study Evaluating Radiotherapy Followed by Durvalumab (MEDI4736) and Ceralasertib (AZD6738)” PMID 40781023 ↗ Jul 2025 “AZD6738 240 mg bid on D15-D28 Every 4 weeks” NCT04298021 ↗ “Ceralasertib \[AZD6738\]” NCT03330847 ↗ “Ceralasertib (AZD6738)” NCT04699838 ↗ “Ceralasertib (AZD6738)” NCT03833440 ↗ |
| Action | Inhibit | “oral ATR (ataxia telangiectasia and Rad3-related) inhibitor” PMID 37934611 ↗ Jan 2024 |
| Modality | Small molecule | — CHEMBL4285417 ↗ |
| Route | Oral | “given orally” NCT01955668 ↗ |
| Target | ATR | “oral ATR (ataxia telangiectasia and Rad3-related) inhibitor ceralasertib (AZD6738)” PMID 37934611 ↗ Jan 2024 |